Shah, Urvi A. http://orcid.org/0000-0001-8419-1091
Whiting, Karissa
Devlin, Sean
Ershler, Rachel
Kanapuru, Bindu
Lee, David J.
Tahri, Sabrin
Gwise, Thomas
Rustad, Even H.
Mailankody, Sham http://orcid.org/0000-0002-2815-9561
Lesokhin, Alexander M.
Kazandjian, Dickran
Maura, Francesco http://orcid.org/0000-0002-5017-1620
Auclair, Daniel
Birmann, Brenda M. http://orcid.org/0000-0002-7550-5498
Usmani, Saad Z.
Gormley, Nicole
Marinac, Catherine R. http://orcid.org/0000-0002-9128-3012
Landgren, Ola http://orcid.org/0000-0001-6485-4839
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748, 2K12CA184746, R25CA203650, F32 CA220859, K22 CA251648)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Allen Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
EIF | Stand Up To Cancer (SU2C-AACR-DT28-18)
Article History
Received: 18 September 2022
Revised: 18 December 2022
Accepted: 20 December 2022
First Online: 12 January 2023
Competing interests
: The authors declare no relevant conflicts of interest. Dr. Shah has received research funding from Celgene/Bristol Myers Squibb and Janssen to her institution, personal fees from Janssen, Sanofi, Bristol Myers Squibb, and honorariums for continuing medical education activity from MJH LifeSciences, MashUpMD and ACCC, all outside of the submitted work. Dr. Marinac has received research funding from GRAIL. Dr Lesokhin reported receiving grants and personal fees from Janssen and Pfizer, and grants from Genentech, Bristol Myers Squibb, and Trillium Therapeutics outside the submitted work. Dr. Mailankody reported receiving other fees from Takeda, Janssen, Bristol Myers Squibb, Allogene Therapeutics, PleXus Education, and Physician Education Resource outside the submitted work. Dr. Landgren reported receiving grants from LLS, the Rising Tide Foundation, Paula and Rodger Riney Foundation, IMF, the National Institutes of Health, Glenmark, Seattle Genetics, Memorial Sloan Kettering, Amgen, and Janssen; personal fees from Amgen, Celgene, and Janssen for invited scientific talks; other fees from Takeda and Janssen for randomized clinical trials, personal fees from Karyopharm, Adaptive Biotech, The Binding Site, Bristol Myers Squibb, Cellectis, Oncopeptides, and Pfizer for invited scientific talks; grants from the Multiple Myeloma Research Foundation for genomic studies and minimal residual disease (MRD) studies in myeloma, from the Perelman Family Foundation for studies on myeloma precursor disease, from the National Cancer Institute for MRD studies in myeloma, and from the US Food and Drug Administration for racial disparities in myeloma; other fees from Theradex for randomized clinical trials and other from Merck outside the submitted work.